Physician profile
Ronald John Polinsky
NPI 1235188319
$57,780.41
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $19K · 2021: $1,076 · 2022: $582 · 2023: $29.85 · 2024: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $278 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $277.90 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $55,864.63 | 2019-2023 | |
| Amgen INC. | $433.11 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $429.19 | 2019-2022 | |
| Pfizer INC. | $296.84 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $144.60 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.66 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $97.01 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $73.75 | 2019 | |
| Boston Scientific Corporation | $46.52 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $45.73 | 2022-2023 | Camzyos |
| Abbott Laboratories | $42.50 | 2019 | |
| Abiomed | $21.48 | 2020 | |
| Merck Sharp & Dohme LLC | $16.34 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.43 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $13.25 | 2021 | |
| Esperion Therapeutics, INC. | $12.37 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Polinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.